Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Italian cohorts
Autor: | Stefano Genovese, Antonio Nicolucci, Mauro Tettamanti, Fabio Robusto, Vito Lepore, Francesco Giorgino, Pierluca Colacioppo, Ida Fortino, Maria Carla Roncaglioni, Antonio D'Ettorre, Fausto Avanzini, Marta Baviera |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism Population 030209 endocrinology & metabolism Type 2 diabetes 030204 cardiovascular system & hematology Lower risk Glucagon-Like Peptide-1 Receptor Brain Ischemia 03 medical and health sciences 0302 clinical medicine Endocrinology Diabetes mellitus Internal medicine Internal Medicine Humans Hypoglycemic Agents Medicine education Sodium-Glucose Transporter 2 Inhibitors education.field_of_study business.industry Proportional hazards model Sodium Hazard ratio medicine.disease Stroke Observational Studies as Topic Glucose Diabetes Mellitus Type 2 Italy Pharmaceutical Preparations Cardiovascular Diseases Cohort business Cohort study |
Zdroj: | Diabetes, Obesity and Metabolism. 23:1484-1495 |
ISSN: | 1463-1326 1462-8902 |
DOI: | 10.1111/dom.14361 |
Popis: | Aim To examine the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with other antihyperglycaemic agents (AHAs) in large and unselected populations of the Lombardy and Apulia regions in Italy. Materials and methods An observational cohort study of first-time users of GLP-1RAs, SGLT2 inhibitors or other AHAs was conducted from 2010 to 2018. Death and cardiovascular (CV) events were evaluated using conditional Cox models in propensity-score-matched populations. Adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated for each region and in a meta-analysis for pooled risks. Results After propensity-score matching, the Lombardy cohort included 18 716 and 11 683 patients and the Apulia cohort 9772 and 6046 patients for the GLP-1RA and SGLT2 inhibitor groups, respectively. Use of GLP-1RAs was associated with lower rates of death (HR 0.61, CI 0.56-0.65, Lombardy; HR 0.63, CI 0.55-0.71, Apulia), cerebrovascular disease and ischaemic stroke (HR 0.70, CI 0.63-0.79; HR 0.72, CI 0.60-0.87, Lombardy), peripheral vascular disease (HR 0.72, CI 0.64-0.82, Lombardy; HR 0.80, CI 0.67-0.98, Apulia), and lower limb complications (HR 0.67, CI 0.56-0.81, Lombardy; HR 0.69, CI 0.51-0.93, Apulia). Compared with other AHAs, SGLT2 inhibitor use decreased the risk of death (HR 0.47, CI 0.40-0.54, Lombardy; HR 0.43, CI 0.32-0.57, Apulia), cerebrovascular disease (HR 0.75, CI 0.61-0.91, Lombardy; HR 0.72, CI 0.54-0.96, Apulia), and heart failure (HR 0.56, CI 0.46-0.70, Lombardy; HR 0.57, CI 0.42-0.77, Apulia). In the pooled cohorts, a reduction in heart failure was also observed with GLP-1RAs (HR 0.89, 95% CI 0.82-0.97). Serious adverse events were quite low in frequency. Conclusion Our findings from real-world practice confirm the favourable effect of GLP-1RAs and SGLT2 inhibitors on death and CV outcomes across both regions consistently. Thus, these drug classes should be preferentially considered in a broad type 2 diabetes population beyond those with CV disease. |
Databáze: | OpenAIRE |
Externí odkaz: |